Heart Health
60 articles on Heart Health, researched and written by the Shotlee Editorial Team from primary sources.
It's Called 'Nature's Ozempic', But Should You Take Psyllium Husk?
Psyllium husk is gaining viral attention for its digestive and metabolic benefits. But is it truly a weight loss solution comparable to GLP-1 medications? We break down the evidence.
8 min read
Semaglutide (Ozempic, Wegovy) Offers Heart Protection Beyond Weight Loss
A groundbreaking study published in The Lancet demonstrates that semaglutide, the active ingredient in Ozempic and Wegovy, provides substantial cardiovascular protection independent of the amount of weight lost. This finding reshapes our understanding of how these GLP-1 receptor agonists benefit heart health.
7 min read
Ozempic vs. Jardiance: Better Heart Protection for Diabetics with AFib
A new study compares GLP-1 and SGLT-2 inhibitors in patients with type 2 diabetes and atrial fibrillation, revealing significant differences in heart health outcomes.
7 min read
GLP-1s and Menopause: Expert Warns of Accelerated Bone Loss Risk
The collision of rapid weight loss driven by GLP-1 medications like Wegovy and Mounjaro with the natural bone density decline of menopause creates a significant, under-discussed risk for women's skeletal health.
6 min read
Retatrutide Phase 3 Results: 28% Weight Loss and the Triple Agonist Promise
Eli Lilly has released pivotal Phase 3 trial data for retatrutide, a triple agonist showing up to 28% body weight reduction and significant improvements in diabetes and sleep apnea.
7 min read
GLP-1 Therapies: Australia's New Blueprint for Obesity and Heart Health
Australia has released a groundbreaking clinical consensus statement on obesity and cardiovascular disease (CVD), marking a pivotal moment in medical practice. This new guidance places GLP-1 receptor agonists—a class of medications including semaglutide and tirzepatide—at the forefront of treatment strategies, offering clinicians a clear, practical pathway for improving patient outcomes.
6 min read
Semaglutide & Heart Health: New Insights on Atrial Fibrillation Prevention
Emerging research from Ben-Gurion University suggests Semaglutide and Colchicine may prevent atrial fibrillation by reducing inflammation and cardiac scarring.
8 min read
Semaglutide for Older Adults: Weight Loss & Heart Health Gains
A comprehensive analysis of the STEP trials reveals that once-weekly semaglutide significantly benefits older adults with obesity, leading to substantial weight loss and improvements in key cardiometabolic markers. This article delves into the findings, implications, and considerations for this important demographic.
7 min read
GLP-1 Medications: Miracle Drug, Wellness Trend, or Vanity?
GLP-1 medications have surged from diabetes treatment to mainstream wellness. This article examines their medical benefits, potential downsides, and the evolving societal perception of weight loss.
7 min read
Severe Obesity and Heart Failure: New Insights into Cardiac Muscle Recovery
A groundbreaking Johns Hopkins study reveals that severe obesity causes intrinsic cardiac muscle weakness, but weight loss can trigger significant recovery.
3 min read
Medicare Expands GLP-1 Coverage: What the 2027 Policy Shift Means for Seniors
The federal government has extended its commitment to fund GLP-1 obesity medications through 2027, shifting away from private insurer mandates to protect seniors from premium hikes.
2 min read
GLP-1s Don't Work for Everyone: What to Know If Not Seeing Results
Started GLP-1s for weight loss or blood sugar control but seeing no results? New research in Genome Medicine reveals that 10% of people carry PAM gene variants linked to weaker responses. Experts explain genetics, common pitfalls, testing, and effective alternatives to help you succeed.
7 min read
Ozempic and GLP-1 Drugs: Heart Benefits and Personal Realities
Thirty million Americans—one in eight—are turning to GLP-1 drugs like Ozempic for weight management and more, with data showing a 20% reduced risk of heart attacks and strokes. But what happens when the weight doesn't budge, as in 10% of users? This personal story explores the hype, realities, and broader implications of these medications.
4 min read
How to Keep Weight Off After Ozempic: Proven Strategies
Stopping Ozempic often leads to weight regain—up to 7% in trials or two-thirds within a year. While continuing semaglutide helps sustain losses, lifestyle changes and maintenance dosing offer alternatives. Work with your healthcare team for a personalized plan to keep the weight off long-term.
6 min read
Inside India's GLP-1 Rush: Generics, Hype, Risks
In India, the GLP-1 rush is on—patients demand Ozempic or Mounjaro by name, generics slash costs to ₹1,290/month, fueled by Instagram and forums. But endocrinologists caution against indiscriminate use amid nausea, rebound weight, and serious risks. Inside the hype reshaping obesity treatment.
5 min read
GLP-1s Aid Health Even Without Weight Loss: New Evidence
While most people on GLP-1 medications like Wegovy experience significant weight loss, 10-15% are non-responders. Emerging research shows these drugs still improve liver health, reduce heart risks, and more—independent of weight changes. A new mouse study reveals why, challenging insurance requirements for weight loss thresholds.
5 min read
GLP-1s Benefit Non-Responders Without Weight Loss: New Evidence
While most people on GLP-1 medications like Wegovy experience dramatic weight loss, 10-15% are non-responders. Emerging research shows these drugs still deliver benefits for liver disease, heart health, and more—independent of the scale. A new study from Dr. Daniel Drucker's lab uncovers why.
5 min read
Taking GLP-1s? Doctors Stress Movement and Mental Health Too
Jelon Smart from Savannah dropped 110 pounds on Ozempic—but credits her intensive workout regimen too. Facing severe ankle swelling from Achilles tendinitis at 285 pounds, she transformed her life. Doctors remind GLP-1 users: movement and mental health are essential alongside medication.
5 min read
Ozempic Users Warned: Don't Skip Exercise, Study Urges
Ozempic users who skip exercise face suboptimal results, according to a new study in Sports Medicine on GLP-1 drugs like Victoza and Saxenda. Among 193 adults, those combining medication with structured workouts saw the best outcomes, while sedentary users fared worst. Meanwhile, one patient's rare blindness side effect highlights ongoing risks.
5 min read
Wegovy Pill Shows Greater Weight Loss Than Foundayo in Novo Study
Novo Nordisk's latest comparison study claims its Wegovy pill delivers superior weight loss compared to Eli Lilly's newly approved Foundayo tablet. The ORION analysis shows a 3.2 percentage point edge for oral semaglutide, plus lower discontinuation rates due to side effects. As oral GLP-1s compete, discover the key findings and implications for patients.
6 min read
Mars CEO Poul Weihrauch Named Novo Nordisk Board Observer
Novo Nordisk, key supplier of GLP-1 drugs like Ozempic and Wegovy, has appointed Mars CEO Poul Weihrauch as a board observer. This move highlights the growing impact of weight-loss medications on food consumption habits. As GLP-1 use rises, food giants are adapting to shifting snack demands.
5 min read
FDA Approves Triple Max Dose of Wegovy: 7.2mg Now Available
The FDA just greenlit a groundbreaking higher dose of Wegovy, tripling the previous maximum to 7.2 milligrams for enhanced weight management. Patients saw up to 21% body weight loss, with unique cardiovascular protections. Here's what this means for obesity treatment and access.
5 min read
Grim Effects of Stopping GLP-1s Like Ozempic, Study Finds
New research paints a stark picture: stopping GLP-1 drugs like Ozempic can rapidly reverse cardiovascular benefits, with risks spiking 8% after just six months. Published in BMJ Medicine, the study tracked over 333,000 adults and warns of 'metabolic whiplash.' Patients face weight regain, inflammation resurgence, and lasting scars from interruptions.
4 min read
Grim Effects of Stopping GLP-1s Like Ozempic, Study Reveals
New research paints a grim picture: stopping GLP-1 drugs like Ozempic can rapidly reverse cardiovascular benefits, with risks spiking 8% after just six months. A Washington University study of over 333,000 patients highlights the 'metabolic whiplash' of discontinuation. Understand the findings and why adherence matters.
5 min read
Morning Squawk: Dow Streak, Fertilizer Prices, Novo Nordisk Wegovy & More
The latest Morning Squawk highlights the Dow's ongoing losing streak, climbing fertilizer prices, and Novo Nordisk's new Wegovy shot amid market volatility. President Trump ramps up criticism of Fed Chair Jerome Powell, urging continued investigation into the 'incompetent' leader. A judge's subpoena block adds tension to Trump's Fed nominee confirmation.
5 min read
How Gila Monster Venom Led Scientists to Ozempic
A venomous desert lizard, the Gila monster, holds a surprising key to one of medicine's biggest breakthroughs: Ozempic. Its venom revealed exendin-4, a stable GLP-1 mimic that paved the way for transformative diabetes therapies. This unlikely origin story highlights nature's role in modern metabolic health.
5 min read
Stopping GLP-1 Drugs May Raise Heart Disease Risk, Study Finds
Popular GLP-1 drugs like semaglutide and tirzepatide offer heart health benefits for type 2 diabetes patients, but stopping them may reverse these gains. A Washington University study of over 333,000 veterans revealed up to 22% higher risk of heart attacks and strokes after discontinuation. Continuous use provides up to 18% risk reduction—here's what it means for long-term treatment.
5 min read
Quitting Ozempic? What Happens When You Stop: Weight Regain & Risks
Stopping Ozempic can lead to full weight regain in about 1.7 years, plus reversal of cardiovascular and metabolic benefits, warns a major BMJ review. Nearly 50% of users discontinue within a year due to side effects and high costs. Doctors urge consulting before quitting to protect your health gains.
5 min read
The Quest for Oral GLP-1s: History and Innovations
For decades, GLP-1 receptor agonists like Ozempic have transformed diabetes and obesity treatment via injections, but patients crave oral options. This guide traces the scientific quest for oral GLP-1s, from early discoveries and Gila monster breakthroughs to Rybelsus challenges and promising algae-based innovations. Understand the barriers and what's next for affordable, pill-based metabolic health.
5 min read
The Himsification of Medicine: Super Bowl Ad & Semaglutide Clash
Hims & Hers made waves with a Super Bowl ad promoting preventive care through tailored prescriptions and peptides for everyday Americans. But announcing compounded oral semaglutide triggered an FDA investigation and a swift lawsuit from Novo Nordisk. The quick settlement highlights battles over GLP-1 access and drug pricing.
4 min read
Babson Fingertip Blood Tests Now Include GLP-1 Monitoring
Babson Diagnostics, crowned Medtech Company of the Year in 2024, now offers GLP-1 monitoring through its innovative fingertip blood tests. Patients on GLP-1 medications like Wegovy can pick up prescriptions and get comprehensive bloodwork in one pharmacy stop. This pea-sized sample panel tracks key metrics for safer, more effective therapy.
7 min read
Aspen Plans Mounjaro Rollout in Sub-Saharan Africa
South Africa's Aspen Pharmacare is accelerating Mounjaro's rollout across sub-Saharan Africa after its explosive success at home, where the GLP-1 market tripled to $133.6 million. With over half the market share and $78.97 million in projected sales, this expansion tests rapid access to advanced weight-loss therapies. Here's how Aspen's KwikPen approval paves the way.
4 min read
This Week in Science: Ozempic's Joint Benefits, Superagers Secrets & More
This week's science news uncovers surprising benefits of Ozempic for joint health beyond weight loss, reveals why superagers stay sharp with more new brain neurons, and highlights food quality over diet type for heart protection. From cholesterol-lowering oatmeal diets to a universal nasal vaccine, these findings offer fresh hope for metabolic and cognitive health.
5 min read
Wegovy and Ozempic May Slash Deadly Heart Attack Complication Risk
Researchers from the University of Bristol and UCL have found that GLP-1 drugs like Wegovy and Ozempic could dramatically reduce the risk of 'no-reflow,' a deadly complication affecting up to half of heart attack patients. By relaxing tiny blood vessels, these medications may prevent further heart damage even if given by paramedics on-site. This study opens doors for repurposing popular obesity and diabetes treatments in emergency cardiac care.
6 min read
Joan Collins, 92, Rejects Ozempic Over 'Disastrous Faces' and Needles
At 92, actress Joan Collins declares she'd 'never dream' of using Ozempic, citing 'too many disastrous faces' and her aversion to needles. This sparks discussion as Kelly Osbourne confronts cruel commentary on her look at the Brit Awards. Learn the medical context behind these celebrity views on GLP-1 drugs.
5 min read
Glenmark to Launch Affordable Semaglutide, Joining Indian Peers
Glenmark Pharmaceuticals is gearing up to launch affordable versions of semaglutide, the blockbuster GLP-1 drug for diabetes and obesity, later this month. This move intensifies competition among Indian drugmakers like Sun Pharma and Dr Reddy's following the March 21 patent expiry. With prices potentially half those of innovators, millions of patients stand to gain better access.
5 min read
Semaglutide May Double nAMD Risk in Older Adults: Study
New research from the University of Toronto reveals that older adults with diabetes taking semaglutide (Ozempic and Wegovy) face more than double the risk of neovascular age-related macular degeneration (nAMD), a severe form of vision loss. The study, published in JAMA Ophthalmology, highlights increased risks with longer use and certain comorbidities. Patients should prioritize regular eye exams to catch issues early.
5 min read
Survey: 3M Canadians on GLP-1 Drugs Like Ozempic, Reshaping Eating and Spending
A new Leger Healthcare survey estimates that around three million Canadian adults are currently using GLP-1 medications such as Ozempic or Mounjaro. These drugs are not only curbing appetite and cravings but also transforming daily spending habits, from less restaurant takeout to more fresh produce and gym memberships. Weight loss tops the reasons, but barriers like cost keep millions from starting.
5 min read
Donna Kelce Denies Weight-Loss Drugs, Credits Intermittent Fasting
Donna Kelce, mother of NFL stars Travis and Jason, is clapping back at online speculation that her slimmer figure on The Traitors came from weight-loss drugs like Ozempic. The 73-year-old reveals she lost about 30 pounds over a year through intermittent fasting alone. Her story highlights natural paths to metabolic health amid GLP-1 hype.
5 min read
Kelly Osbourne Blasts Cruel Remarks on Brit Awards Look
While Ozzy Osbourne received a posthumous lifetime achievement award at the Brit Awards, online focus shifted to Kelly Osbourne's appearance with cruel comments. In an emotional Instagram post, Kelly called out the lack of compassion during her hardest time. This echoes prior backlash accusing her of Ozempic use amid grief.
6 min read
Abbott Partners with Novo for Semaglutide Extensior in India
Abbott has tied up with Novo Nordisk India to commercialize Extensior, the second brand of semaglutide injection following Ozempic's launch. This move positions Abbott as the second firm with sole distribution rights for Novo's semaglutide portfolio in India, after Emcure Pharma. With demand surging and generics on the horizon, here's what it means for patients.
4 min read
$3,000 Minipigs Powering Europe's Drug Pipeline
In eastern Denmark, Ellegaard Gottingen Minipigs A/S breeds specialized $3,000 minipigs vital to Europe's drug pipeline, including Novo Nordisk's Ozempic and Wegovy. These biosecure facilities address supply chain vulnerabilities exposed by the pandemic's monkey shortages. As the EU pushes for biotech independence, these smaller, human-like pigs offer a strategic alternative.
6 min read
Healthy Lifestyle Enhances GLP-1 Therapy's CV Benefits in Type 2 Diabetes
New research reveals that pairing GLP-1 receptor agonists with healthy lifestyle habits significantly lowers heart attack, stroke, and CV death risk in type 2 diabetes patients. Those following 6-8 habits plus GLP-1 therapy saw a 43% reduced MACE risk. This study highlights their complementary roles in heart health.
5 min read
Tirzepatide in Mounjaro Cuts Alcohol Intake Over 50%, Study Shows
The weight-loss drug Mounjaro's active ingredient, tirzepatide, is showing promise beyond metabolic health by slashing alcohol intake in animal models. A new study from the University of Gothenburg found it reduced voluntary consumption by over 50%, curbed binge drinking, and prevented relapse. This could signal a new avenue for treating alcohol use disorder through GLP-1/GIP receptor agonism.
6 min read
Temu Peptides: Why Buying Them Seems Bad
Silicon Valley's biohacking craze has hit Temu, where peptides are sold for pennies, raising alarms about safety and purity. From BPC-157 vials to questionable GLP-1s, these products bypass rigorous testing. A closer look reveals why this mainstream shift could be disastrous for health.
5 min read
Semaglutide: Artificial Shortage as Novo Nordisk's Business Model?
Novo Nordisk's lawsuit against Hims & Hers claims compounded semaglutide sales are illegal now that shortages ended. But is this about patient safety or enforcing high prices like $150/month for Wegovy pills versus $50 alternatives? Dive into how patents create artificial semaglutide shortages.
5 min read
Mounjaro Sales Hit $7.4B as Regulators Ban Social Media Ads; Tirzepatide Link...
Eli Lilly reports Mounjaro sales skyrocketing to $7.4 billion in Q4 2026, driven by explosive GLP-1 demand. New 2026 research links tirzepatide to liver inflammation resolution and reduced heart failure risks. Meanwhile, UK regulators ban unauthorized social media promotions of these prescription drugs.
5 min read
Founder Targets $50B GLP-1 Market with Natural Alternative
In a $50 billion GLP-1 market dominated by injectables like Ozempic, Becca McCarthy is carving out space with Evolv—a natural pill for appetite control. Teaming with a molecular biologist, she's delivering GLP-1-like effects without stigma or synthetics. Here's how she's challenging the prescription-only model.
5 min read
Oral Semaglutide Reduces Heart Failure Risk in Type 2 Diabetes: SOUL Trial
New analysis from the SOUL trial reveals oral semaglutide significantly reduces heart failure risks in type 2 diabetes patients who already have the condition. This benefit is especially notable in HFpEF cases, without compromising safety. Discover the details and implications for managing cardiometabolic disease.
5 min read
GLP-1 Era Nutrition Symposium on Cardiac Recovery Held in Dhaka
A pivotal symposium on 'Nutrition in Clinical Practice: From GLP-1 Era to Cardiac Recovery' drew 150 nutrition professionals to Dhaka's KIB Convention Hall. Chaired by renowned dietician Akhtarun Nahar Alo, the event featured keynote speakers from NICVD and BIRDEM, followed by the launch of Nutricaa Limited's OPTIMA meal replacement. This gathering highlights the growing intersection of GLP-1 therapies and targeted nutrition for cardiac recovery.
5 min read
Serena Williams Weight Loss: GLP-1 Transformation Revealed
Tennis icon Serena Williams has shared her inspiring weight loss story, dropping 34 pounds with GLP-1 drugs after struggling post-retirement and motherhood. Facing unknown heart disease risks, she credits the medication with transforming her health. Inside her journey and how GLP-1 works for real results.
5 min read
Super Bowl LX Ads Feature AI, GLP-1 Drugs & Celebs from Clooney to Jenner
Super Bowl LX is set to showcase a surge in GLP-1 weight-loss drug ads from telehealth giants like Ro featuring Serena Williams and Novo Nordisk's Ozempic and Wegovy. With record $8-10M ad slots, health trends dominate alongside AI and celebrity-packed spots with George Clooney and Kendall Jenner. This 'GLP-1 Super Bowl' highlights booming demand for metabolic health solutions.
6 min read
Generic Ozempic & Wegovy in India: Patient Guide
Generic versions of blockbuster GLP-1 drugs Ozempic and Wegovy are now approved in India, promising lower costs and wider access. Patients can expect semaglutide generics from Sun Pharma, Zydus Lifesciences, and others amid patent expiry in 2026. This guide breaks down the science, benefits, and key considerations for safe use.
4 min read
Oxford Study: GLP-1 Weight Regain, Food Matters More
A new University of Oxford study reveals that GLP-1 users regain weight rapidly after stopping medications like Ozempic, with cardiometabolic benefits reversing within two years. This underscores the need for portion-controlled, nutrient-dense foods to maintain satiety on fewer calories. Food innovation will play a key role in supporting former users.
3 min read
Cardiologist: GLP-1 Drugs Benefits Beyond Weight Loss for Heart, Liver
Cardiologist Dmitry Yaranov states GLP-1 drugs like Ozempic, Wegovy, and Mounjaro offer benefits far beyond weight loss. They enhance cardiovascular health, combat fatty liver disease, and improve blood sugar control in diabetes patients. These medications could redefine treatment for heart, liver, and metabolic diseases.
1 min read
Novo Nordisk official notes substantial enthusiasm for Wegovy weight reduction pill
A Novo Nordisk official has highlighted significant interest in the company's Wegovy oral weight-loss tablet. The pill, launched recently, offers similar results to the injectable version at a more affordable price. It also provides secondary benefits for heart health.
3 min read
Nature's Ozempic: Can This OTC Supplement Truly Meet Weight Loss Expectations?
Many people turn to GLP-1 drugs like Ozempic for weight loss, but cost can be a barrier. Affordable alternatives like berberine offer hope, yet experts caution against unrealistic hype. This article examines its benefits, side effects, and potential as a weight loss aid.
3 min read
Berberine: Is This Supplement Truly 'Nature's Ozempic?' Experts Weigh In
Berberine, a compound found in several plants, has gained attention for its potential health benefits, including weight loss and blood sugar regulation. Some compare it to Ozempic, but experts caution about its effectiveness and safety compared to prescription medications.
4 min read
Research Indicates Common Diabetes Medication May Inhibit Exercise Gains
New research suggests that a widely prescribed diabetes drug, metformin, might diminish some key advantages of exercise. The study indicated that individuals taking metformin experienced less improvement in blood sugar management and blood vessel performance compared to those who exercised without the medication.
4 min read
Obesity Crisis in America Meets Ozempic Boom: Data Shows GLP-1 Hotspots
A recent report highlights the increasing use of GLP-1 medications like Ozempic and Mounjaro across the United States, with some states showing greater adoption than others. The data suggests a correlation between obesity rates and GLP-1 prescription rates, particularly in the South and Midwest.
3 min read